Drugs Details

Drugs Info of First Lansoprazole, Prevacid, Prevacid OTC, Prevacid SoluTab
Drugs Details
  • Drugs Type  : FDA
  • Date : 24th Mar 2015 01:07 am
  • Brand Name : First Lansoprazole, Prevacid, Prevacid OTC, Prevacid SoluTab
  • Generic Name : lansoprazole (Pronunciation: lan SOE pra zol)
Descriptions

The active ingredient in PREVACID Delayed-Release Capsules and PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets is lansoprazole, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C16H14F3N3O2S with a molecular weight of 369.37. PREVACID has the following structure:

 

PREVACID(lansoprazole) Structural Formula Illustration

Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Lansoprazole is stable when exposed to light for up to two months. The rate of degradation of the compound in aqueous solution increases with decreasing pH. The degradation half-life of the drug substance in aqueous solution at 25°C is approximately 0.5 hour at pH 5.0 and approximately 18 hours at pH 7.0.

PREVACID is supplied in delayed-release capsules and in delayed-release orally disintegrating tablets for oral administration.

The delayed-release capsules are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per capsule. Each delayed-release capsule contains enteric-coated granules consisting of 15 mg or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: sugar sphere, sucrose, methacrylic acid copolymer, low substituted hydroxypropyl cellulose, starch, magnesium carbonate, talc, polyethylene glycol, titanium dioxide, polysorbate 80, hydroxypropyl cellulose, colloidal silicon dioxide, D&C Red No. 28, FD&C Blue No. 1, FD&C Green No. 31, and FD&C Red No. 40.

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets are available in two dosage strengths: 15 mg and 30 mg of lansoprazole per tablet. Each delayed-release orally disintegrating tablet contains enteric-coated microgranules consisting of 15 mg or 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: mannitol, methacrylic acid, hydroxypropyl cellulose, lactose monohydrate-microcrystalline cellulose sphere, triethyl citrate, crospovidone, polyacrylate, magnesium carbonate, aspartame2, glyceryl monostearate, hypromellose, magnesium stearate, citric acid, titanium dioxide, talc, artificial strawberry flavor, polyethylene glycol, polysorbate 80 and ferric oxide.

REFERENCES

1 PREVACID 15-mg capsules only.

2 Phenylketonurics: Contains Phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.

What are the possible side effects of lansoprazole (First Lansoprazole, Prevacid, Prevacid OTC, Prevacid SoluTab)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using lansoprazole and call your doctor at once if you have symptoms of low magnesium:

  • dizziness, confusion;
  • fast or uneven heart rate;
  • jerky muscle movements;
  • feeling jittery;
  • diarrhea that is watery or bloody;
  • muscle cramps, muscle weakness or limp feeling;
  • cough or choking feeling;...

Read All Potential Side Effects and See Pictures of Prevacid »

What are the precautions when taking lansoprazole (Prevacid)?

Before taking lansoprazole, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as dexlansoprazole, omeprazole, pantoprazole); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease.

Some symptoms may actually be signs of a more serious condition. Get medical help right away if you have: heartburn with lightheadedness/sweating/dizziness, chest/jaw/arm/shoulder pain (especially with shortness of breath, unusual sweating), unexplained weight loss.

In addition, before you self-treat with this medication,...

Read All Potential Precautions of Prevacid »


This monograph has been modified to include the generic and brand name in many instances.

Indications

Short-Term Treatment Of Active Duodenal Ulcer

PREVACID is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see Clinical Studies].

H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Triple Therapy: PREVACID/amoxicillin/clarithromycin

PREVACID in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies].

Please refer to the full prescribing information for amoxicillin and clarithromycin.

Dual Therapy: PREVACID/amoxicillin

PREVACID in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Clinical Studies].

Please refer to the full prescribing information for amoxicillin.

Maintenance Of Healed Duodenal Ulcers

PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see Clinical Studies].

Short-Term Treatment Of Active Benign Gastric Ulcer

PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see Clinical Studies].

Healing Of NSAID-Associated Gastric Ulcer

PREVACID is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see Clinical Studies].

Risk Reduction Of NSAID-Associated Gastric Ulcer

PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see Clinical Studies].

Gastroesophageal Reflux Disease (GERD)

Short-Term Treatment of Symptomatic GERD

PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see Clinical Studies].

Short-Term Treatment of Erosive Esophagitis

PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered [see Clinical Studies].

Maintenance Of Healing Of Erosive Esophagitis (EE)

PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see Clinical Studies].

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES)

PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see Clinical Studies].

 

Dosage Administration

PREVACID is available as a capsule and an orally disintegrating tablet, and is available in 15 mg and 30 mg strengths. Directions for use specific to the route and available methods of administration for each of these dosage forms is presented below. PREVACID should be taken before eating. PREVACID products SHOULD NOT BE CRUSHED OR CHEWED. In the clinical trials, antacids were used concomitantly with PREVACID.

Recommended Dose

 

Indication Recommended Dose Frequency
Duodenal Ulcers
Short-Term Treatment 15 mg Once daily for 4 weeks
Maintenance of Healed 15 mg Once daily
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence*
  Triple Therapy:
    PREVACID 30 mg Twice daily (q12h) for 10 or 14 days
    Amoxicillin 1 gram Twice daily (q12h) for 10 or 14 days
    Clarithromycin 500 mg Twice daily (q12h) for 10 or 14 days
  Dual Therapy:
    PREVACID 30 mg Three times daily (q8h) for 14 days
    Amoxicillin 1 gram Three times daily (q8h) for 14 days
Benign Gastric Ulcer
  Short-Term Treatment 30 mg Once daily for up to 8 weeks
NSAID-associated Gastric Ulcer
  Healing 30 mg Once daily for 8 weeks†
  Risk Reduction 15 mg Once daily for up to 12 weeks†
Gastroesophageal Reflux Disease (GERD)
  Short-Term Treatment of Symptomatic GERD 15 mg Once daily for up to 8 weeks
  Short-Term Treatment of Erosive Esophagitis 30 mg Once daily for up to 8 weeks‡
Pediatric
(1 to 11 years of age) Short-Term Treatment of Symptomatic GERD and Short-Term Treatment of Erosive Esophagitis
   ≤ 30 kg 15 mg Once daily for up to 12 weeks§
   > 30 kg 30 mg Once daily for up to 12 weeks§
(12 to 17 years of age) Short-Term Treatment of Symptomatic GERD
  Nonerosive GERD 15 mg Once daily for up to 8 weeks
  Erosive Esophagitis 30 mg Once daily for up to 8 weeks
Maintenance of Healing of Erosive Esophagitis 15 mg Once daily#
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome 60 mg Once daily¶
*Please refer to amoxicillin and clarithromycin full prescribing information for CONTRAINDICATIONS and WARNINGS, and for information regarding dosing in elderly and renally-impaired patients.
†Controlled studies did not extend beyond indicated duration.
‡For patients who do not heal with PREVACID for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis, an additional 8 week course of PREVACID may be considered.
§The PREVACID dose was increased (up to 30 mg twice daily) in some pediatric patients after 2 or more weeks of treatment if they remained symptomatic. For pediatric patients unable to swallow an intact capsule please see Administration Options.
¶Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg twice daily have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison Syndrome have been treated continuously with PREVACID for more than 4 years.
# Controlled studies did not extend beyond 12 months

Patients should be instructed that if a dose is missed, it should be taken as soon as possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.

Special Populations

Renal impairment patients and geriatric patients do not require dosage adjustment. However, consider dose adjustment in patients with severe liver impairment [see Use in Specific Populations].

Important Administration Information

Administration Options

PREVACID Delayed-Release Capsules – Oral Administration

  • PREVACID Delayed-Release Capsules should be swallowed whole.
  • Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows:
    • Open capsule.
    • Sprinkle intact granules on one tablespoon of either applesauce, ENSURE pudding, cottage cheese, yogurt or strained pears.
    • Swallow immediately.
  • PREVACID Delayed-Release Capsules may also be emptied into a small volume of either apple juice, orange juice or tomato juice and administered as follows:
    • Open capsule.
    • Sprinkle intact granules into a small volume of either apple juice, orange juice or tomato juice (60 mL – approximately 2 ounces).
    • Mix briefly.
    • Swallow immediately.
    • To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.

PREVACID Delayed-Release Capsules – Nasogastric Tube ( ≥ 16 French) Administration

  • For patients who have a nasogastric tube in place, PREVACID Delayed-Release Capsules can be administered as follows:
    • Open capsule.
    • Mix intact granules into 40 mL of apple juice. DO NOT USE OTHER LIQUIDS.
    • Inject through the nasogastric tube into the stomach.
    • Flush with additional apple juice to clear the tube.

USE IN OTHER FOODS AND LIQUIDS HAS NOT BEEN STUDIED CLINICALLY AND IS THEREFORE NOT RECOMMENDED.

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets

  • PREVACID SoluTab should not be broken or cut.
  • PREVACID SoluTab should not be chewed.
    • Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed.
    • The tablet typically disintegrates in less than 1 minute.
    • Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID SoluTab can be delivered in two different ways.

PREVACID SoluTab – Oral Syringe

For administration via oral syringe, PREVACID SoluTab can be administered as follows:

  • Place a 15 mg tablet in oral syringe and draw up 4 mL of water, or place a 30 mg tablet in oral syringe and draw up 10 mL of water.
  • Shake gently to allow for a quick dispersal.
  • After the tablet has dispersed, administer the contents within 15 minutes.
  • Refill the syringe with approximately 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and administer any remaining contents.

PREVACID SoluTab – Nasogastric Tube ( ≥ 8 French) Administration

For administration via a nasogastric tube, PREVACID SoluTab can be administered as follows:

  • Place a 15 mg tablet in a syringe and draw up 4 mL of water, or place a 30 mg tablet in a syringe and draw up 10 mL of water.
  • Shake gently to allow for a quick dispersal.
  • After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.
  • Refill the syringe with approximately 5 mL of water, shake gently, and flush the nasogastric tube.

How Supplied

Dosage Forms And Strengths

  • 15 mg capsules are opaque, hard gelatin, colored pink and green with the TAP logo and “PREVACID 15” imprinted on the capsule.
  • 30 mg capsules are opaque, hard gelatin, colored pink and black with the TAP logo and “PREVACID 30” imprinted on the capsule.
  • 15 mg tablets are white to yellowish white, uncoated, colored orange to dark brown speckles with “15” debossed on one side of the tablet.
  • 30 mg tablets are white to yellowish white, uncoated, colored orange to dark brown speckles with “30” debossed on one side of the tablet.

Storage And Handling

PREVACID Delayed-Release Capsules, 15 mg, are opaque, hard gelatin, colored pink and green with “TAP” and “PREVACID 15” imprinted on the capsules. The 30 mg capsules are opaque, hard gelatin, colored pink and black with “TAP” and “PREVACID 30” imprinted on the capsules. They are available as follows:

NDC 64764-541-30 Unit of use bottles of 30: 15-mg capsules
NDC
64764-541-19 Bottles of 1000: 15-mg capsules
NDC
64764-541-11 Unit dose package of 100: 15-mg capsules
NDC
64764-046-13 Bottles of 100: 30-mg capsules
NDC
64764-046-19 Bottles of 1000: 30-mg capsules
NDC 64764-046-11 Unit dose package of 100: 30-mg capsules

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets, 15 mg, are white to yellowish white uncoated tablets with orange to dark brown speckles, with “15” debossed on one side of the tablet. The 30 mg are white to yellowish white uncoated tablets with orange to dark brown speckles, with “30” debossed on one side of the tablet. The tablets are available as follows:

NDC 64764-543-11 Unit dose packages of 100: 15-mg tablets
NDC
64764-544-11 Unit dose packages of 100: 30-mg tablets

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F)[see USP Controlled Room Temperature].

Distributed by: Takeda Pharmaceuticals America, Inc., Deerfield, IL 60015. Revised: December 2014


This monograph has been modified to include the generic and brand name in many instances.

 

Side Effects

Clinical

Worldwide, over 10,000 patients have been treated with PREVACID in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment. In general, PREVACID treatment has been well-tolerated in both short-term and long-term trials.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The following adverse reactions were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of PREVACID-treated patients and occurred at a greater rate in PREVACID-treated patients than placebo-treated patients in Table 1.

Table 1: Incidence of Possibly or Probably Treatment-Related Adverse Reactions in Short-Term, Placebo-Controlled PREVACID Studies

Body System/Adverse Event PREVACID
(N= 2768) %
Placebo
(N= 1023) %
Body as a Whole
Abdominal Pain 2.1 1.2
Digestive System
Constipation 1.0 0.4
Diarrhea 3.8 2.3
Nausea 1.3 1.2

Headache was also seen at greater than 1% incidence but was more common on placebo. The incidence of diarrhea was similar between patients who received placebo and patients who received 15 mg and 30 mg of PREVACID, but higher in the patients who received 60 mg of PREVACID (2.9%, 1.4%, 4.2%, and 7.4%, respectively).

The most commonly reported possibly or probably treatment-related adverse event during maintenance therapy was diarrhea.

In the risk reduction study of PREVACID for NSAID-associated gastric ulcers, the incidence of diarrhea for patients treated with PREVACID, misoprostol, and placebo was 5%, 22%, and 3%, respectively.

Another study for the same indication, where patients took either a COX-2 inhibitor or lansoprazole and naproxen, demonstrated that the safety profile was similar to the prior study. Additional reactions from this study not previously observed in other clinical trials with PREVACID included contusion, duodenitis, epigastric discomfort, esophageal disorder, fatigue, hunger, hiatal hernia, hoarseness, impaired gastric emptying, metaplasia, and renal impairment.

Additional adverse experiences occurring in less than 1% of patients or subjects who received PREVACID in domestic trials are shown below:

Body as a Whole – abdomen enlarged, allergic reaction, asthenia, back pain, candidiasis, carcinoma, chest pain (not otherwise specified), chills, edema, fever, flu syndrome, halitosis, infection (not otherwise specified), malaise, neck pain, neck rigidity, pain, pelvic pain

Cardiovascular System – angina, arrhythmia, bradycardia, cerebrovascular accident/cerebral infarction, hypertension/hypotension, migraine, myocardial infarction, palpitations, shock (circulatory failure), syncope, tachycardia, vasodilation

Digestive System – abnormal stools, anorexia, bezoar, cardiospasm, cholelithiasis, colitis, dry mouth, dyspepsia, dysphagia, enteritis, eructation, esophageal stenosis, esophageal ulcer, esophagitis, fecal discoloration, flatulence, gastric nodules/fundic gland polyps, gastritis, gastroenteritis, gastrointestinal anomaly, gastrointestinal disorder, gastrointestinal hemorrhage, glossitis, gum hemorrhage, hematemesis, increased appetite, increased salivation, melena, mouth ulceration, nausea and vomiting, nausea and vomiting and diarrhea, gastrointestinal moniliasis, rectal disorder, rectal hemorrhage, stomatitis, tenesmus, thirst, tongue disorder, ulcerative colitis, ulcerative stomatitis

Endocrine System – diabetes mellitus, goiter, hypothyroidism

Hemic and Lymphatic System – anemia, hemolysis, lymphadenopathy

Metabolism and Nutritional Disorders – avitaminosis, gout, dehydration, hyperglycemia/hypoglycemia, peripheral edema, weight gain/loss

Musculoskeletal System – arthralgia, arthritis, bone disorder, joint disorder, leg cramps, musculoskeletal pain, myalgia, myasthenia, ptosis, synovitis

Nervous System – abnormal dreams, agitation, amnesia, anxiety, apathy, confusion, convulsion, dementia, depersonalization, depression, diplopia, dizziness, emotional lability, hallucinations, hemiplegia, hostility aggravated, hyperkinesia, hypertonia, hypesthesia, insomnia, libido decreased/increased, nervousness, neurosis, paresthesia, sleep disorder, somnolence, thinking abnormality, tremor, vertigo

Respiratory System – asthma, bronchitis, cough increased, dyspnea, epistaxis, hemoptysis, hiccup, laryngeal neoplasia, lung fibrosis, pharyngitis, pleural disorder, pneumonia, respiratory disorder, upper respiratory inflammation/infection, rhinitis, sinusitis, stridor

Skin and Appendages – acne, alopecia, contact dermatitis, dry skin, fixed eruption, hair disorder, maculopapular rash, nail disorder, pruritus, rash, skin carcinoma, skin disorder, sweating, urticaria

Special Senses – abnormal vision, amblyopia, blepharitis, blurred vision, cataract, conjunctivitis, deafness, dry eyes, ear/eye disorder, eye pain, glaucoma, otitis media, parosmia, photophobia, retinal degeneration/disorder, taste loss, taste perversion, tinnitus, visual field defect

Urogenital System – abnormal menses, breast enlargement, breast pain, breast tenderness, dysmenorrhea, dysuria, gynecomastia, impotence, kidney calculus, kidney pain, leukorrhea, menorrhagia, menstrual disorder, penis disorder, polyuria, testis disorder, urethral pain, urinary frequency, urinary retention, urinary tract infection, urinary urgency, urination impaired, vaginitis.

Postmarketing Experience

Additional adverse experiences have been reported since PREVACID has been marketed. The majority of these cases are foreign-sourced and a relationship to PREVACID has not been established. Because these reactions were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events are listed below by COSTART body system.

Body as a Whole – anaphylactic/anaphylactoid reactions; Digestive System – hepatotoxicity, pancreatitis, vomiting; Hemic and Lymphatic System –agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, and thrombotic thrombocytopenic purpura; Infections and Infestations – Clostridium difficile associated diarrhea; Metabolism and Nutritional Disorders – hypomagnesemia; Musculoskeletal System – bone fracture, myositis; Skin and Appendages – severe dermatologic reactions including erythema multiforme, Stevens- Johnson syndrome, toxic epidermal necrolysis (some fatal); Special Senses – speech disorder; Urogenital System – interstitial nephritis, urinary retention.

Combination Therapy With Amoxicillin And Clarithromycin

In clinical trials using combination therapy with PREVACID plus amoxicillin and clarithromycin, and PREVACID plus amoxicillin, no adverse reactions peculiar to these drug combinations were observed. Adverse reactions that have occurred have been limited to those that had been previously reported with PREVACID, amoxicillin, or clarithromycin.

Triple Therapy: PREVACID/amoxicillin/clarithromycin

The most frequently reported adverse reactions for patients who received triple therapy for 14 days were diarrhea (7%), headache (6%), and taste perversion (5%). There were no statistically significant differences in the frequency of reported adverse reactions between the 10- and 14-day triple therapy regimens. No treatment-emergent adverse reactions were observed at significantly higher rates with triple therapy than with any dual therapy regimen.

Dual Therapy: PREVACID/amoxicillin

The most frequently reported adverse reactions for patients who received PREVACID three times daily plus amoxicillin three times daily dual therapy were diarrhea (8%) and headache (7%). No treatment-emergent adverse reactions were observed at significantly higher rates with PREVACID three times daily plus amoxicillin three times daily dual therapy than with PREVACID alone.

For information about adverse reactions with antibacterial agents (amoxicillin and clarithromycin) indicated in combination with PREVACID, refer to the ADVERSE REACTIONS section of their package inserts.

Laboratory Values

The following changes in laboratory parameters in patients who received PREVACID were reported as adverse reactions:

Abnormal liver function tests, increased SGOT (AST), increased SGPT (ALT), increased creatinine, increased alkaline phosphatase, increased globulins, increased GGTP, increased/decreased/abnormal WBC, abnormal AG ratio, abnormal RBC, bilirubinemia, blood potassium increased, blood urea increased, crystal urine present, eosinophilia, hemoglobin decreased, hyperlipemia, increased/decreased electrolytes, increased/decreased cholesterol, increased glucocorticoids, increased LDH, increased/decreased/abnormal platelets, increased gastrin levels and positive fecal occult blood. Urine abnormalities such as albuminuria, glycosuria, and hematuria were also reported. Additional isolated laboratory abnormalities were reported.

In the placebo controlled studies, when SGOT (AST) and SGPT (ALT) were evaluated, 0.4% (4/978) and 0.4% (11/2677) patients, who received placebo and PREVACID, respectively, had enzyme elevations greater than three times the upper limit of normal range at the final treatment visit. None of these patients who received PREVACID reported jaundice at any time during the study.

In clinical trials using combination therapy with PREVACID plus amoxicillin and clarithromycin, and PREVACID plus amoxicillin, no increased laboratory abnormalities particular to these drug combinations were observed.

For information about laboratory value changes with antibacterial agents (amoxicillin and clarithromycin) indicated in combination with PREVACID, refer to the ADVERSE REACTIONS section of their package inserts.

Read the Prevacid (lansoprazole) Side Effects Center for a complete guide to possible side effects

Interactions

Drugs With pH-Dependent Absorption Kinetics

Due to its effects on gastric acid secretion, lansoprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ampicillin esters, ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with PREVACID [see CLINICAL PHARMACOLOGY].

PREVACID is likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, PREVACID should not be co-administered with atazanavir [see CLINICAL PHARMACOLOGY].

Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving PPIs and MMF. Use PREVACID with caution in transplant patients receiving MMF.

Warfarin

In a study of healthy subjects, co-administration of single or multiple 60 mg doses of PREVACID and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time [see CLINICAL PHARMACOLOGY]. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time [see CLINICAL PHARMACOLOGY].

Tacrolimus

Concomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.

Theophylline

A minor increase (10%) in the clearance of theophylline was observed following the administration of PREVACID concomitantly with theophylline. Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when PREVACID is started or stopped to ensure clinically effective blood levels [see CLINICAL PHARMACOLOGY].

Clopidogrel

Concomitant administration of lansoprazole and clopidogrel in healthy subjects had no clinically important effect on exposure to the active metabolite of clopidogrel or clopidogrel-induced platelet inhibition [see CLINICAL PHARMACOLOGY]. No dose adjustment of clopidogrel is necessary when administered with an approved dose of PREVACID.

Methotrexate

Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of high dose methotrexate with PPIs have been conducted [see WARNINGS AND PRECAUTIONS].

In a study of rheumatoid arthritis patients receiving low-dose methotrexate, PREVACID and naproxen, no effect on pharmacokinetics of methotrexate was observed [see CLINICAL PHARMACOLOGY].

Combination Therapy With Clarithromycin

Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions due to drug interactions [see WARNINGS AND PRECAUTIONS in prescribing information for clarithromycin]. Because of these drug interactions, clarithromycin is contraindicated for co-administration with certain drugs [see CONTRAINDICATIONS in prescribing information for clarithromycin].

For information about drug interactions of antibacterial agents (amoxicillin and clarithromycin) indicated in combination with PREVACID, refer to the DRUG INTERACTIONS section of their package inserts.

Read the Prevacid Drug Interactions Center for a complete guide to possible interactions

Learn More »


This monograph has been modified to include the generic and brand name in many instances.

Warnings

Included as part of the PRECAUTIONS section.

Precautions

Gastric Malignancy

Symptomatic response to therapy with lansoprazole does not preclude the presence of gastric malignancy.

Acute Interstitial Nephritis

Acute interstitial nephritis has been observed in patients taking PPIs including PREVACID. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue PREVACID if acute interstitial nephritis develops [see CONTRAINDICATIONS].

Cyanocobalamin (vitamin B12) Deficiency

Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.

Clostridium Difficile Associated Diarrhea

Published observational studies suggest that proton pump inhibitor (PPI) therapy like PREVACID may be associated with an increased risk of Clostridium difficile associated diarrhea (CDAD), especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see ADVERSE REACTIONS].

Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

CDAD has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with PREVACID, refer to WARNINGS AND PRECAUTIONS sections of those package inserts.

Bone Fracture

Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS].

Hypomagnesemia

Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see ADVERSE REACTIONS].

Concomitant Use Of PREVACID With Methotrexate

Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY]

Patient Counseling Information

[See FDA-Approved Medication Guide and Patient Instructions for Use]

Patient should be informed of the following:

  • Advise patients to immediately report and seek care for diarrhea that does not improve. This may be a sign of Clostridium difficile associated diarrhea [see WARNINGS AND PRECAUTIONS
  • Advise patients to immediately report and seek care for any cardiovascular or neurological symptoms including palpitations, dizziness, seizures, and tetany as these may be signs of hypomagnesemia [see WARNINGS AND PRECAUTIONS].
Information For Patients

PREVACID is available as a capsule and an orally disintegrating tablet, and is available in 15 mg and 30 mg strengths. Directions for use specific to the route and available methods of administration for each of these dosage forms is presented below [see DOSAGE AND ADMINISTRATION].

  • PREVACID should be taken before eating.
  • PREVACID products SHOULD NOT BE CRUSHED OR CHEWED.
  • Phenylketonurics: Contains Phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.
Administration Options

1. PREVACID Delayed-Release Capsules – Oral Administration

  • PREVACID Delayed-Release Capsules should be swallowed whole.
  • Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows:
    • Open capsule.
    • Sprinkle intact granules on one tablespoon of either applesauce, ENSURE pudding, cottage cheese, yogurt or strained pears.
    • Swallow immediately.
  • PREVACID Delayed-Release Capsules may also be emptied into a small volume of either apple juice, orange juice or tomato juice and administered as follows:
    • Open capsule.
    • Sprinkle intact granules into a small volume of either apple juice, orange juice or tomato juice (60 mL – approximately 2 ounces).
    • Mix briefly.
    • Swallow immediately.
    • To ensure complete delivery of the dose, the glass should be rinsed with two or more volumes of juice and the contents swallowed immediately.

PREVACID Delayed-Release Capsules – Nasogastric Tube ( ≥ 16 French) Administration

  • For patients who have a nasogastric tube in place, PREVACID Delayed-Release Capsules can be administered as follows:
    • Open capsule.
    • Mix intact granules into 40 mL of apple juice. DO NOT USE OTHER LIQUIDS.
    • Inject through the nasogastric tube into the stomach.
    • Flush with additional apple juice to clear the tube.

USE IN OTHER FOODS AND LIQUIDS HAS NOT BEEN STUDIED CLINICALLY AND IS THEREFORE NOT RECOMMENDED.

2. PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets

  • PREVACID SoluTab should not be broken or cut.
  • PREVACID SoluTab should not be chewed.
    • Place the tablet on the tongue and allow it to disintegrate, with or without water, until the particles can be swallowed.
    • The tablet typically disintegrates in less than 1 minute.
    • Alternatively, for children or other patients who have difficulty swallowing tablets, PREVACID SoluTab can be delivered in two different ways.

PREVACID SoluTab – Oral Syringe

For administration via oral syringe, PREVACID SoluTab can be administered as follows:

  • Place a 15 mg tablet in oral syringe and draw up 4 mL of water, or place a 30 mg tablet in oral syringe and draw up 10 mL of water.
  • Shake gently to allow for a quick dispersal.
  • After the tablet has dispersed, administer the contents within 15 minutes.
  • Refill the syringe with approximately 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and administer any remaining contents.

PREVACID SoluTab – Nasogastric Tube ( ≥ 8 French) Administration

For administration via a nasogastric tube, PREVACID SoluTab can be administered as follows:

  • Place a 15 mg tablet in a syringe and draw up 4 mL of water, or place a 30 mg tablet in a syringe and draw up 10 mL of water.
  • Shake gently to allow for a quick dispersal.
  • After the tablet has dispersed, inject through the nasogastric tube into the stomach within 15 minutes.
  • Refill the syringe with approximately 5 mL of water, shake gently, and flush the nasogastric tube.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

In two 24-month carcinogenicity studies, Sprague-Dawley rats were treated with oral lansoprazole doses of 5 to 150 mg/kg/day, about 1 to 40 times the exposure on a body surface (mg/m²) basis of a 50 kg person of average height [1.46 m² body surface area (BSA)] given the recommended human dose of 30 mg/day. Lansoprazole produced dose-related gastric enterochromaffin-like (ECL) cell hyperplasia and ECL cell carcinoids in both male and female rats. It also increased the incidence of intestinal metaplasia of the gastric epithelium in both sexes. In male rats, lansoprazole produced a dose-related increase of testicular interstitial cell adenomas. The incidence of these adenomas in rats receiving doses of 15 to 150 mg/kg/day (4 to 40 times the recommended human dose based on BSA) exceeded the low background incidence (range = 1.4 to 10%) for this strain of rat.

In a 24-month carcinogenicity study, CD-1 mice were treated with oral lansoprazole doses of 15 to 600 mg/kg/day, 2 to 80 times the recommended human dose based on BSA. Lansoprazole produced a dose-related increased incidence of gastric ECL cell hyperplasia. It also produced an increased incidence of liver tumors (hepatocellular adenoma plus carcinoma). The tumor incidences in male mice treated with 300 and 600 mg/kg/day (40 to 80 times the recommended human dose based on BSA) and female mice treated with 150 to 600 mg/kg/day (20 to 80 times the recommended human dose based on BSA) exceeded the ranges of background incidences in historical controls for this strain of mice. Lansoprazole treatment produced adenoma of rete testis in male mice receiving 75 to 600 mg/kg/day (10 to 80 times the recommended human dose based on BSA).

A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.

Lansoprazole was positive in the Ames test and the in vitro human lymphocyte chromosomal aberration assay. Lansoprazole was not genotoxic in the ex vivo rat hepatocyte unscheduled DNA synthesis (UDS) test, the in vivo mouse micronucleus test, or the rat bone marrow cell chromosomal aberration test.

Lansoprazole at oral doses up to 150 mg/kg/day (40 times the recommended human dose based on BSA) was found to have no effect on fertility and reproductive performance of male and female rats.

Use In Specific Populations

Pregnancy

Teratogenic effects

Pregnancy Category B. Reproduction studies have been performed in pregnant rats at oral doses up to 40 times the recommended human dose and in pregnant rabbits at oral doses up to 16 times the recommended human dose and have revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed [see Nonclinical Toxicology].

See full prescribing information for clarithromycin before using in pregnant women.

Nursing Mothers

Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, taking into account the importance of lansoprazole to the mother.

Pediatric Use

The safety and effectiveness of PREVACID have been established in pediatric patients 1 to 17 years of age for short-term treatment of symptomatic GERD and erosive esophagitis, however, PREVACID was not effective in patients with symptomatic GERD 1 month to less than 1 year of age in a multicenter, double-blind, placebo controlled study.

Neonate To Less Than 1 Year Of Age

The pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged less than 28 days and 1 to 11 months. Compared to healthy adults receiving 30 mg, neonates had higher exposure (mean weight-based normalized AUC values 2.04- and 1.88-fold higher at doses of 0.5 mg/kg/day and 1 mg/kg/day, respectively). Infants aged ≤ 10 weeks had clearance and exposure values that were similar to neonates. Infants aged greater than 10 weeks who received 1 mg/kg/day had mean AUC values that were similar to adults who received a 30 mg dose.

Lansoprazole was not found to be effective in a U.S. and Polish 4 week multicenter, double-blind, placebo-controlled, parallel-group study of 162 patients between one month and less than 12 months of age with symptomatic GERD based on a medical history of crying/fussing/irritability associated with feedings who had not responded to conservative GERD management (i.e., non-pharmacologic intervention) for 7 to 14 days. Patients received lansoprazole as a suspension daily (0.2 to 0.3 mg/kg/day in infants ≤ 10 weeks of age or 1.0 to 1.5 mg/kg/day in infants greater than 10 weeks or placebo) for up to 4 weeks of double-blind treatment.

The primary efficacy endpoint was assessed by greater than 50% reduction from baseline in either the percent of feedings with a crying/fussing/irritability episode or the duration (minutes) of a crying/fussing/irritability episode within one hour after feeding.

There was no difference in the percentage of responders between the lansoprazole pediatric suspension group and placebo group (54% in both groups).

There were no adverse events reported in pediatric clinical studies (1 month to less than 12 months of age) that were not previously observed in adults.

Based on the results of the Phase 3 efficacy study, lansoprazole was not shown to be effective. Therefore, these results do not support the use of lansoprazole in treating symptomatic GERD in infants.

One To 11 Years Of Age

In an uncontrolled, open-label, U.S. multicenter study, 66 pediatric patients (1 to 11 years of age) with GERD were assigned, based on body weight, to receive an initial dose of either PREVACID 15 mg daily if ≤ 30 kg or PREVACID 30 mg daily if greater than 30 kg administered for 8 to 12 weeks. The PREVACID dose was increased (up to 30 mg twice daily) in 24 of 66 pediatric patients after 2 or more weeks of treatment if they remained symptomatic. At baseline 85% of patients had mild to moderate overall GERD symptoms (assessed by investigator interview), 58% had non-erosive GERD and 42% had erosive esophagitis (assessed by endoscopy).

After 8 to 12 weeks of PREVACID treatment, the intent-to-treat analysis demonstrated an approximate 50% reduction in frequency and severity of GERD symptoms.

Twenty-one of 27 erosive esophagitis patients were healed at 8 weeks and 100% of patients were healed at 12 weeks by endoscopy (Table 2).

Table 2: GERD Symptom Improvement and Erosive Esophagitis Healing Rates in Pediatric Patients Age 1 to 11

GERD Final Visit* % (n/N)
Symptomatic GERD
  Improvement in Overall GERD Symptoms† 76% (47/62*)
Erosive Esophagitis
  Improvement in Overall GERD Symptoms† 81% (22/27)
  Healing Rate 100% (27/27)
* At Week 8 or Week 12
† Symptoms assessed by patients diary kept by caregiver.
‡No data were available for 4 pediatric patients.

In a study of 66 pediatric patients in the age group 1 year to 11 years old after treatment with PREVACID given orally in doses of 15 mg daily to 30 mg twice daily, increases in serum gastrin levels were similar to those observed in adult studies. Median fasting serum gastrin levels increased 89% from 51 pg/mL at baseline to 97 pg/mL [interquartile range (25th to 75th percentile) of 71 to 130 pg/mL] at the final visit.

The pediatric safety of PREVACID Delayed-Release Capsules has been assessed in 66 pediatric patients aged 1 to 11 years of age. Of the 66 patients with GERD 85% (56/66) took PREVACID for 8 weeks and 15% (10/66) took it for 12 weeks.

The most frequently reported (2 or more patients) treatment-related adverse reactions in patients 1 to 11 years of age (N=66) were constipation (5%) and headache (3%).

Twelve To 17 Years Of Age

In an uncontrolled, open-label, U.S. multicenter study, 87 adolescent patients (12 to 17 years of age) with symptomatic GERD were treated with PREVACID for 8 to 12 weeks. Baseline upper endoscopies classified these patients into two groups: 64 (74%) nonerosive GERD and 23 (26%) erosive esophagitis (EE). The nonerosive GERD patients received PREVACID 15 mg daily for 8 weeks and the EE patients received PREVACID 30 mg daily for 8 to 12 weeks. At baseline, 89% of these patients had mild to moderate overall GERD symptoms (assessed by investigator interviews). During 8 weeks of PREVACID treatment, adolescent patients experienced a 63% reduction in frequency and a 69% reduction in severity of GERD symptoms based on diary results.

Twenty-one of 22 (95.5%) adolescent erosive esophagitis patients were healed after 8 weeks of PREVACID treatment. One patient remained unhealed after 12 weeks of treatment (Table 3).

Table 3: GERD Symptom Improvement and Erosive Esophagitis Healing Rates in Pediatric Patients Age 12 to 17

GERD Final Visit % (n/N)
Symptomatic GERD (All Patients)
  Improvement in Overall GERD Symptoms* 73.2% (60/82)†
Nonerosive GERD *  
  Improvement in Overall GERD Symptoms* 71.2% (42/59)†
Erosive Esophagitis  
  Improvement in Overall GERD Symptoms* 78.3% (18/23)
  Healing Rate‡ 95.5% (21/22)*
*Symptoms assessed by patient diary (parents/caregivers as necessary).
†No data available for 5 patients.
‡Data from one healed patient was excluded from this analysis due to timing of final endoscopy.

In these 87 adolescent patients, increases in serum gastrin levels were similar to those observed in adult studies, median fasting serum gastrin levels increased 42% from 45 pg/mL at baseline to 64 pg/mL [interquartile range (25th to 75th percentile) of 44 to 88 pg/mL] at the final visit. (Normal serum gastrin levels are 25 to 111 pg/mL.)

The safety of PREVACID Delayed-Release Capsules has been assessed in these 87 adolescent patients. Of the 87 adolescent patients with GERD, 6% (5/87) took PREVACID for less than 6 weeks, 93% (81/87) for 6 to 10 weeks, and 1% (1/87) for greater than 10 weeks. The most frequently reported (at least 3%) treatment-related adverse reactions in these patients were headache (7%), abdominal pain (5%), nausea (3%) and dizziness (3%). Treatment-related dizziness, reported in this package insert as occurring in less than 1% of adult patients, was reported in this study by 3 adolescent patients with nonerosive GERD, who had dizziness concurrently with other reactions (such as migraine, dyspnea, and vomiting).

Geriatric Use

No dosage adjustment of PREVACID is necessary in geriatric patients. The incidence rates of PREVACID-associated adverse reactions and laboratory test abnormalities are similar to those seen in younger patients [see CLINICAL PHARMACOLOGY].

Renal Impairment

No dosage adjustment of PREVACID is necessary in patients with renal impairment. The pharmacokinetics of lansoprazole in patients with various degrees of renal impairment were not substantially different compared to those in subjects with normal renal function [see CLINICAL PHARMACOLOGY].

Hepatic Impairment

In patients with various degrees of chronic hepatic impairment, an increase in the mean AUC of up to 500% was observed at steady state compared to healthy subjects. Consider dose reduction in patients with severe hepatic impairment [see CLINICAL PHARMACOLOGY].

Gender

Over 4,000 women were treated with PREVACID. Ulcer healing rates in females were similar to those in males. The incidence rates of adverse reactions in females were similar to those seen in males [see CLINICAL PHARMACOLOGY].

Race

The pooled mean pharmacokinetic parameters of PREVACID from twelve U.S. Phase 1 studies (N=513) were compared to the mean pharmacokinetic parameters from two Asian studies (N=20). The mean AUCs of PREVACID in Asian subjects were approximately twice those seen in pooled U.S. data; however, the inter-individual variability was high. The Cmax values were comparable.


This monograph has been modified to include the generic and brand name in many instances.

OverDose

PREVACID is not removed from the circulation by hemodialysis. In one reported overdose, a patient consumed 600 mg of PREVACID with no adverse reaction. Oral PREVACID doses up to 5000 mg/kg in rats [approximately 1300 times the 30 mg human dose based on body surface area (BSA)] and in mice (about 675.7 times the 30 mg human dose based on BSA) did not produce deaths or any clinical signs.

ContrainDications

PREVACID is contraindicated in patients with known severe hypersensitivity to any component of the formulation of PREVACID. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria [see ADVERSE REACTIONS].

For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with PREVACID, refer to the CONTRAINDICATIONS section of their package inserts.


This monograph has been modified to include the generic and brand name in many instances.

Clinical Pharamacology

Mechanism Of Action

PREVACID (lansoprazole) belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity.

Pharmacodynamics

Antisecretory Activity

After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4. Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output. In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion. Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin.

The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:

Table 4: Mean Antisecretory Effects After Single and Multiple Daily PREVACID Dosing

  PREVACID
Parameter Baseline Value 15mg 30mg
Day 1 Day 5 Day 1 Day 5
Mean 24 Hour pH 2.1 2.7* 4.0* 3.6* 4.9*
Mean Nighttime pH 1.9 2.4 3.0* 2.6 3.8*
% Time Gastric pH > 3 18 33* 59* 51* 72*
% Time Gastric pH > 4 12 22* 49* 41* 66*
NOTE: An intragastric pH of greater than 4 reflects a reduction in gastric acid by 99%.
*(p < 0.05) versus baseline only.
†(p < 0.05) versus baseline and lansoprazole 15 mg.

After the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole. After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole.

Acid suppression may enhance the effect of antimicrobials in eradicating Helicobacter pylori (H. pylori). The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of PREVACID given daily, twice daily and three times daily (Table 5).

Table 5: Mean Antisecretory Effects After 5 Days of Twice Daily and Three Times Daily Dosing

Parameter PREVACID
30 mg daily 15 mg twice daily 30 mg twice daily 30 mg three times daily
% Time Gastric pH > 5 43 47 59* 77*
% Time Gastric pH > 6 20 23 28 45*
*(p < 0.05) versus PREVACID 30 mg daily
†(p < 0.05) versus PREVACID 30 mg daily, 15 mg twice daily and 30 mg twice daily.

The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses. There was no indication of rebound gastric acidity.

Enterochromaffin-like (ECL) Cell Effects

During lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats. Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies. Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving longterm therapy with lansoprazole [see Nonclinical Toxicology].

Other Gastric Effects in Humans

Lansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach. Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen. Lansoprazole significantly slowed the gastric emptying of digestible solids. Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection. As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer. No significant increase in nitrosamine concentrations was observed.

Serum Gastrin Effects

In over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole. These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy.

Endocrine Effects

Human studies for up to one year have not detected any clinically significant effects on the endocrine system. Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and somatotropic hormone (STH). Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function. In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function. In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats.

Other Effects

No systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans. Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months. After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen.

Microbiology

Lansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section [see INDICATIONS AND USAGE].

Helicobacter Pylori Pretreatment Resistance

Clarithromycin pretreatment resistance ( ≥ 2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399).

Amoxicillin pretreatment susceptible isolates ( ≤ 0.25 mcg/mL) occurred in 97.8% (936/957) and 98.0% (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively. Twenty-one of 957 patients (2.2%) by E-test, and 2 of 100 patients (2.0%) by agar dilution, had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL. One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of H. pylori (Table 6).

Table 6: Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes*

Clarithromycin Pretreatment Results Clarithromycin Post-treatment Results
H. pylori negative -eradicated H. pylori positive - not eradicated Post-treatment susceptibility results
S† I† R† No MIC
Triple Therapy 14-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) (M95-399, M93-131, M95-392)
Susceptible† 112 105       7
Intermediate† 3 3        
Resistant† 17 6     7 4
Triple Therapy 10-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) (M95-399)
Susceptible† 42 40 1   1  
Intermediate†            
Resistant† 4 1     3  
*Includes only patients with pretreatment clarithromycin susceptibility test results
†Susceptible (S) MIC ≤ 0.25 mcg/mL, Intermediate (I) MIC 0.5 to 1.0 mcg/mL, Resistant (R) MIC ≥ 2 mcg/mL

Patients not eradicated of H. pylori following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant H. pylori. Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible. Patients with clarithromycin resistant H. pylori should not be treated with lansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent.

Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes

In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs ( ≤ 0.25 mcg/mL) were eradicated of H. pylori. Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the H. pylori eradicated. A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily/amoxicillin 1 g three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10- and 14-day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy. Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant H. pylori isolates.

Susceptibility Test for Helicobacter pylori

For susceptibility testing information about Helicobacter pylori, see Microbiology section in prescribing information for clarithromycin and amoxicillin.

Pharmacokinetics

PREVACID Delayed-Release Capsules and PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets contain an enteric-coated granule formulation of lansoprazole. Absorption of lansoprazole begins only after the granules leave the stomach. Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours. After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (Cmax) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose. Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing.

Absorption

The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%. In healthy subjects, the mean (±SD) plasma half-life was 1.5 (±1.0) hours. Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals.

Distribution

Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL.

Metabolism

Lansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell. The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion.

Elimination

Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.

Specific Populations

Pediatric Use

One To 17 Years Of Age

The pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged 1 to 11 years and 12 to 17 years in two separate clinical studies. In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing ≤ 30 kg and 30 mg daily for subjects weighing greater than 30 kg. Mean Cmax and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study. In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily. Mean Cmax and AUC values of lansoprazole were not affected by body weight or age; and nearly doseproportional increases in mean Cmax and AUC values were observed between the two dose groups in the study. Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects.

Neonate To Less Than One Year Of Age

Refer to Section 8.4 for the pharmacokinetics of lansoprazole in pediatric patients with GERD aged less than 28 days and 1 to 11 months.

Geriatric Use

The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole. Peak plasma levels were not increased in the elderly. No dosage adjustment is necessary in the elderly [see Use In Specific Populations].

Renal Impairment

In patients with severe renal impairment, plasma protein binding decreased by 1.0% to 1.5% after administration of 60 mg of lansoprazole. Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound). The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the Cmax and Tmax (time to reach the maximum concentration) were not different than the Cmax and Tmax from subjects with normal renal function. No dosage adjustment is necessary in patients with renal impairment [see Use In Specific Populations].

Hepatic Impairment

In patients with various degrees of chronic hepatic impairment, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours. An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects. Consider dose reduction in patients with severe hepatic impairment [see Use in Specific Populations].

Gender

In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results [see Use in Specific Populations].

Drug-Drug Interactions

PREVACID may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).

PREVACID is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that PREVACID does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects. These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.

Atazanavir

PREVACID causes long-lasting inhibition of gastric acid secretion. PREVACID substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, PREVACID, or other proton pump inhibitors, should not be co-administered with atazanavir.

Theophylline

When PREVACID was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when PREVACID is started or stopped to ensure clinically effective blood levels.

Warfarin

In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole. However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including PREVACID, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.

Methotrexate and 7-hydromethotrexate

In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and PREVACID 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted. However, this study was conducted with low doses of methotrexate. A drug interaction study with high doses of methotrexate has not been conducted.

Amoxicillin

PREVACID has also been shown to have no clinically significant interaction with amoxicillin.

Sucralfate

In a single-dose crossover study examining PREVACID 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate. In clinical trials, antacids were administered concomitantly with PREVACID and there was no evidence of a change in the efficacy of PREVACID.

Clopidogrel

Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects who were CYP2C19 extensive metabolizers, receiving once daily administration of clopidogrel 75 mg alone or concomitantly with PREVACID 30 mg (n=40), for 9 days was conducted. The mean AUC of the active metabolite of clopidogrel was reduced by approximately 14% (mean AUC ratio was 86%, with 90% CI of 80 to 92%) when PREVACID was coadministered compared to administration of clopidogrel alone. Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation (induced by 5 mcM ADP) was related to the change in the exposure to clopidogrel active metabolite. The clinical significance of this finding is not clear.

Animal Toxicology And/Or Pharmacology

Reproductive Toxicology Studies

Reproduction studies have been performed in pregnant rats at oral lansoprazole doses up to 150 mg/kg/day [40 times the recommended human dose (30 mg/day) based on body surface area (BSA)] and pregnant rabbits at oral lansoprazole doses up to 30 mg/kg/day (16 times the recommended human dose based on BSA) and have revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole.

Clinical Studies

Duodenal Ulcer

In a U.S. multicenter, double-blind, placebo-controlled, dose-response (15, 30, and 60 mg of PREVACID once daily) study of 284 patients with endoscopically documented duodenal ulcer, the percentage of patients healed after two and four weeks was significantly higher with all doses of PREVACID than with placebo. There was no evidence of a greater or earlier response with the two higher doses compared with PREVACID 15 mg. Based on this study and the second study described below, the recommended dose of PREVACID in duodenal ulcer is 15 mg per day (Table 7).

Table 7: Duodenal Ulcer Healing Rates

Week PREVACID Placebo
(N=72)
15 mg daily
(N=68)
30 mg daily
(N=74)
60 mg daily
(N=70)
2 42.4%* 35.6%* 39.1%* 11.3%
4 89.4%* 91.7%* 89.9%* 46.1%
*(p ≤ 0.001) versus placebo.

PREVACID 15 mg was significantly more effective than placebo in relieving day and nighttime abdominal pain and in decreasing the amount of antacid taken per day.

In a second U.S. multicenter study, also double-blind, placebo-controlled, dose-comparison (15 and 30 mg of PREVACID once daily), and including a comparison with ranitidine, in 280 patients with endoscopically documented duodenal ulcer, the percentage of patients healed after four weeks was significantly higher with both doses of PREVACID than with placebo. There was no evidence of a greater or earlier response with the higher dose of PREVACID. Although the 15 mg dose of PREVACID was superior to ranitidine at 4 weeks, the lack of significant difference at 2 weeks and the absence of a difference between 30 mg of PREVACID and ranitidine leaves the comparative effectiveness of the two agents undetermined (Table 8) [see INDICATIONS AND USAGE].

Table 8: Duodenal Ulcer Healing Rates

Week PREVACID Ranitidine 300 mg h.s.
(N=82)
Placebo
(N=41)
15 mg daily
(N=80)
30 mg daily
(N=77)
2 35.0% 44.2% 30.5% 34.2%
4 92.3%* 80.3%* 70.5%* 47.5%
*(p ≤ 0.05) versus placebo and ranitidine.
†(p ≤ 0.05) versus placebo.
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

Randomized, double-blind clinical studies performed in the U.S. in patients with H. pylori and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within one year) evaluated the efficacy of PREVACID in combination with amoxicillin capsules and clarithromycin tablets as triple 14- day therapy or in combination with amoxicillin capsules as dual 14-day therapy for the eradication of H. pylori. Based on the results of these studies, the safety and efficacy of two different eradication regimens were established:

Triple therapy: PREVACID 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily

Dual therapy: PREVACID 30 mg three times daily/amoxicillin 1 g three times daily

All treatments were for 14 days. H. pylori eradication was defined as two negative tests (culture and histology) at 4 to 6 weeks following the end of treatment.

Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

A randomized, double-blind clinical study performed in the U.S. in patients with H. pylori and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within one year) compared the efficacy of PREVACID triple therapy for 10 and 14 days. This study established that the 10-day triple therapy was equivalent to the 14-day triple therapy in eradicating H. pylori (Tables 9 and 10) [see INDICATIONS AND USAGE].

Table 9: H. pylori Eradication Rates – Triple Therapy (PREVACID/amoxicillin/clarithromycin) Percent of Patients Cured [95% Confidence Interval] (Number of patients)

Study Duration Triple Therapy Evaluable Analysis* Triple Therapy Intent-to-Treat Analysis†
M93-131 14 days 92‡ [80.0-97.7] (N=48) 86‡ [73.3-93.5] (N=55)
M95-392 14 days 86§ [75.7-93.6] (N=66) 83§ [72.0-90.8] (N=70)
M95-399¶ 14 days 85 [77.0-91.0] (N=113) 82 [73.9-88.1] (N=126)
10 days 84 [76.0-89.8] (N=123) 81 [73.9-87.6] (N=135)
*Based on evaluable patients with confirmed duodenal ulcer (active or within one year) and H. pylori infection at baseline defined as at least two of three positive endoscopic tests from CLOtest, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the evaluable analysis as failures of therapy.
†Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within one year). All dropouts were included as failures of therapy.
‡(p < 0.05) versus PREVACID/amoxicillin and PREVACID/clarithromycin dual therapy.
§(p < 0.05) versus clarithromycin/amoxicillin dual therapy.
¶The 95% confidence interval for the difference in eradication rates, 10-day minus 14-day is (-10.5, 8.1) in the evaluable analysis and (-9.7, 9.1) in the intent-to-treat analysis.

Table 10: H. pylori Eradication Rates – 14-Day Dual Therapy (PREVACID/amoxicillin) Percent of Patients Cured [95% Confidence Interval] (Number of patients)

  Dual Therapy Evaluable Analysis Dual Therapy Intent-to-Treat Analysis†
M93-131 77‡[62.5-87.2](N=51) 70‡[56.8-81.2](N=60)
M93-125 66§[51.9-77.5](N=58) 61 §[48.5-72.9](N=67)
*Based on evaluable patients with confirmed duodenal ulcer (active or within one year) and H. pylori infection at baseline defined as at least two of three positive endoscopic tests from CLOtest, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy.
†Patients were included in the analysis if they had documented H. pylori infection at baseline as defined above and had a confirmed duodenal ulcer (active or within one year). All dropouts were included as failures of therapy.
‡ (p < 0.05) versus PREVACID alone.
§ (p < 0.05) versus PREVACID alone or amoxicillin alone.
Long-Term Maintenance Treatment of Duodenal Ulcers

PREVACID has been shown to prevent the recurrence of duodenal ulcers. Two independent, double-blind, multicenter, controlled trials were conducted in patients with endoscopically confirmed healed duodenal ulcers. Patients remained healed significantly longer and the number of recurrences of duodenal ulcers was significantly less in patients treated with PREVACID than in patients treated with placebo over a 12-month period (Table 11) [see INDICATIONS AND USAGE].

Table 11: Endoscopic Remission Rates

Trial Drug No. of Pts. Percent in Endoscopic Remission
0-3 mo. 0-6 mo. 0-12 mo.
#1 PREVACID 15 mg daily 86 90%* 87%* 84%*
Placebo 83 49% 41% 39%
#2 PREVACID 30 mg daily 18 94%* 94%* 85%*
PREVACID 15 mg daily 15 87%* 79%* 70%*
Placebo 15 33% 0% 0%
%=Life Table Estimate
*(p ≤ 0.001) versus placebo.

In trial #2, no significant difference was noted between PREVACID 15 mg and 30 mg in maintaining remission.

Gastric Ulcer

In a U.S. multicenter, double-blind, placebo-controlled study of 253 patients with endoscopically documented gastric ulcer, the percentage of patients healed at four and eight weeks was significantly higher with PREVACID 15 mg and 30 mg once a day than with placebo (Table 12) [see INDICATIONS AND USAGE].

Table 12: Gastric Ulcer Healing Rates

Week PREVACID Placebo
(N=64)
15 mg daily
(N=65)
30 mg daily
(N=63)
60 mg daily
(N=61)
4 64.6%* 58.1%* 53.3%* 37.5%
8 92.2%* 96.8%* 93.2%* 76.7%
*(p ≤ 0.05) versus placebo.

Patients treated with any PREVACID dose reported significantly less day and night abdominal pain along with fewer days of antacid use and fewer antacid tablets used per day than the placebo group.

Independent substantiation of the effectiveness of PREVACID 30 mg was provided by a meta-analysis of published and unpublished data.

Healing of NSAID-Associated Gastric Ulcer

In two U.S. and Canadian multicenter, double-blind, active-controlled studies in patients with endoscopically confirmed NSAID-associated gastric ulcer who continued their NSAID use, the percentage of patients healed after 8 weeks was statistically significantly higher with 30 mg of PREVACID than with the active control. A total of 711 patients were enrolled in the study, and 701 patients were treated. Patients ranged in age from 18 to 88 years (median age 59 years), with 67% female patients and 33% male patients. Race was distributed as follows: 87% Caucasian, 8% Black, 5% Other. There was no statistically significant difference between PREVACID 30 mg daily and the active control on symptom relief (i.e., abdominal pain) (Table 13) [see INDICATIONS AND USAGE].

Table 13: NSAID-Associated Gastric Ulcer Healing Rates

Study #1
  PREVACID 30 mg daily Active Control
Week 4 60% (53/88) ‡ 28% (23/83)†
Week 8 79% (62/79) ‡ 55% (41/74)
Study #2
  PREVACID 30 mg daily Active Control
Week 4 53% (40/75) 38% (31/82)
Week 8 77% (47/61) ‡ 50% (33/66)
*Actual observed ulcer(s) healed at time points ±2 days
†Dose for healing of gastric ulcer
‡ (p ≤ 0.05) versus the active control
Risk Reduction of NSAID-Associated Gastric Ulcer

In one large U.S., multicenter, double-blind, placebo- and misoprostol-controlled (misoprostol blinded only to the endoscopist) study in patients who required chronic use of an NSAID and who had a history of an endoscopically documented gastric ulcer, the proportion of patients remaining free from gastric ulcer at 4, 8, and 12 weeks was significantly higher with 15 or 30 mg of PREVACID than placebo. A total of 537 patients were enrolled in the study, and 535 patients were treated. Patients ranged in age from 23 to 89 years (median age 60 years), with 65% female patients and 35% male patients. Race was distributed as follows: 90% Caucasian, 6% Black, 4% other. The 30 mg dose of PREVACID demonstrated no additional benefit in risk reduction of the NSAID-associated gastric ulcer than the 15 mg dose (Table 14) [see INDICATIONS AND USAGE].

Table 14: Proportion of Patients Remaining Free of Gastric Ulcers*

Week PREVACID 15 mg daily
(N=121)
PREVACID 30 mg daily
(N=116)
Misoprostol 200 mcg four times daily
(N=106)
Placebo
(N=112)
4 90% 92% 96% 66%
8 86% 88% 95% 60%
12 80% 82% 93% 51%
*% = Life Table Estimate
(p < 0.001) PREVACID 15 mg daily versus placebo; PREVACID 30 mg daily versus placebo; and misoprostol 200 mcg four times daily versus placebo.
(p < 0.05) Misoprostol 200 mcg four times daily versus PREVACID 15 mg daily; and misoprostol 200 mcg four times daily versus PREVACID30 mg daily.
Gastroesophageal Reflux Disease (GERD)

Symptomatic GERD

In a U.S. multicenter, double-blind, placebo-controlled study of 214 patients with frequent GERD symptoms, but no esophageal erosions by endoscopy, significantly greater relief of heartburn associated with GERD was observed with the administration of lansoprazole 15 mg once daily up to 8 weeks than with placebo. No significant additional benefit from lansoprazole 30 mg once daily was observed.

The intent-to-treat analyses demonstrated significant reduction in frequency and severity of day and night heartburn. Data for requency and severity for the 8-week treatment period are presented in Table 15 and in Figures 1 and 2:

Table 15: Frequency of Heartburn

Variable Placebo
(n=43)
PREVACID 15 mg
(n=80)
PREVACID 30 mg
(n=86)
Median
% of Days without Heartburn
  Week 1 0% 71%* 46%*
  Week 4 11% 81%* 76%*
  Week 8 13% 84%* 82%*
% of Nights without Heartburn
  Week 1 17% 86%* 57%*
  Week 4 25% 89%* 73%*
  Week 8 36% 92%* 80%*
*(p < 0.01) versus placebo.

Figure 1

Mean severity of day heart burn - Illustration

Figure 2

Mean severity of night heart burn - Illustration

In two U.S., multicenter double-blind, ranitidine-controlled studies of 925 total patients with frequent GERD symptoms, but no esophageal erosions by endoscopy, lansoprazole 15 mg was superior to ranitidine 150 mg (twice daily) in decreasing the frequency and severity of day and night heartburn associated with GERD for the 8-week treatment period. No significant additional benefit from lansoprazole 30 mg once daily was observed [see INDICATIONS AND USAGE].

Erosive Esophagitis

In a U.S. multicenter, double-blind, placebo-controlled study of 269 patients entering with an endoscopic diagnosis of esophagitis with mucosal grading of 2 or more and grades 3 and 4 signifying erosive disease, the percentages of patients with healing are presented in Table 16:

Table 16: Erosive Esophagitis Healing Rates

Week PREVACID Placebo
(N=63)
15 mg daily
(N=69)
30 mg daily
(N=65)
60 mg daily
(N=72)
4 67.6%* 81.3% *† 80.6%*† 32.8%
6 87.7%* 95.4%* 94.3%* 52.5%
8 90.9%* 95.4%* 94.4%* 52.5%
*(p ≤ 0.001) versus placebo.
†(p ≤ 0.05) versus PREVACID 15 mg.

In this study, all PREVACID groups reported significantly greater relief of heartburn and less day and night abdominal pain along with fewer days of antacid use and fewer antacid tablets taken per day than the placebo group. Although all doses were effective, the earlier healing in the higher two doses suggests 30 mg daily as the recommended dose.

PREVACID was also compared in a U.S. multicenter, double-blind study to a low dose of ranitidine in 242 patients with erosive reflux esophagitis. PREVACID at a dose of 30 mg was significantly more effective than ranitidine 150 mg twice daily as shown below (Table 17).

Table 17: Erosive Esophagitis Healing Rates

Week PREVACID 30 mg daily
(N=115)
Ranitidine 150 mg twice daily
(N=127)
2 66.7%* 38.7%
4 82.5%* 52.0%
6 93.0%* 67.8%
8 92.1%* 69.9%
*(p ≤ 0.001) versus ranitidine.

In addition, patients treated with PREVACID reported less day and nighttime heartburn and took less antacid tablets for fewer days than patients taking ranitidine 150 mg twice daily.

Although this study demonstrates effectiveness of PREVACID in healing erosive esophagitis, it does not represent an adequate comparison with ranitidine because the recommended ranitidine dose for esophagitis is 150 mg four times daily, twice the dose used in this study.

In the two trials described and in several smaller studies involving patients with moderate to severe erosive esophagitis, PREVACID produced healing rates similar to those shown above.

In a U.S. multicenter, double-blind, active-controlled study, 30 mg of PREVACID was compared with ranitidine 150 mg twice daily in 151 patients with erosive reflux esophagitis that was poorly responsive to a minimum of 12 weeks of treatment with at least one H2-receptor antagonist given at the dose indicated for symptom relief or greater, namely, cimetidine 800 mg/day, ranitidine 300 mg/day, famotidine 40 mg/day or nizatidine 300 mg/day. PREVACID 30 mg was more effective than ranitidine 150 mg twice daily in healing reflux esophagitis, and the percentage of patients with healing were as follows. This study does not constitute a comparison of the effectiveness of histamine H2-receptor antagonists with PREVACID, as all patients had demonstrated unresponsiveness to the histamine H2-receptor antagonist mode of treatment. It does indicate, however, that PREVACID may be useful in patients failing on a histamine H2-receptor antagonist (Table 18) [see INDICATIONS AND USAGE].

Table 18: Reflux Esophagitis Healing Rates in Patients Poorly Responsive to Histamine H2-Receptor Antagonist Therapy

Week PREVACID 30 mg daily
(N=100)
Ranitidine 150 mg twice daily
(N=51)
4 74.7%* 42.6%
8 83.7%* 32.0%
*(p ≤ 0.001) versus ranitidine.
Long-Term Maintenance Treatment of Erosive Esophagitis

Two independent, double-blind, multicenter, controlled trials were conducted in patients with endoscopically confirmed healed esophagitis. Patients remained in remission significantly longer and the number of recurrences of erosive esophagitis was significantly less in patients treated with PREVACID than in patients treated with placebo over a 12-month period (Table 19).

Table 19: Endoscopic Remission Rates

Trial Drug No. of Pts. Percent in Endoscopic Remission
0-3 mo. 0-6 mo. 0-12 mo.
#1 PREVACID 15 mg daily 59 83%* 81%* 79%*
PREVACID 30 mg daily 56 93%* 93%* 90%*
Placebo 55 31% 27% 24%
#2 PREVACID 15 mg daily 50 74%* 72%* 67%*
PREVACID 30 mg daily 49 75%* 72%* 55%*
Placebo 47 16% 13% 13%
%=Life Table Estimate
*(p ≤ 0.001) versus placebo.

Regardless of initial grade of erosive esophagitis, PREVACID 15 mg and 30 mg were similar in maintaining remission.

In a U.S., randomized, double-blind, study, PREVACID 15 mg daily (n = 100) was compared with ranitidine 150 mg twice daily (n = 106), at the recommended dosage, in patients with endoscopically-proven healed erosive esophagitis over a 12-month period. Treatment with PREVACID resulted in patients remaining healed (Grade 0 lesions) of erosive esophagitis for significantly longer periods of time than those treated with ranitidine (p < 0.001). In addition, PREVACID was significantly more effective than ranitidine in providing complete relief of both daytime and nighttime heartburn. Patients treated with PREVACID remained asymptomatic for a significantly longer period of time than patients treated with ranitidine [see INDICATIONS AND USAGE].

Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome

In open studies of 57 patients with pathological hypersecretory conditions, such as Zollinger-Ellison syndrome (ZES) with or without multiple endocrine adenomas, PREVACID significantly inhibited gastric acid secretion and controlled associated symptoms of diarrhea, anorexia and pain. Doses ranging from 15 mg every other day to 180 mg per day maintained basal acid secretion below 10 mEq/hr in patients without prior gastric surgery and below 5 mEq/hr in patients with prior gastric surgery.

Initial doses were titrated to the individual patient need, and adjustments were necessary with time in some patients [see DOSAGE AND ADMINISTRATION]. PREVACID was well tolerated at these high dose levels for prolonged periods (greater than four years in some patients). In most ZES patients, serum gastrin levels were not modified by PREVACID. However, in some patients, serum gastrin increased to levels greater than those present prior to initiation of lansoprazole therapy [see INDICATIONS AND USAGE].

REFERENCES

1. National Committee for Clinical Laboratory Standards. Summary Minutes, Subcommittee on Antimicrobial Susceptibility Testing, Tampa, FL, January 11-13, 1998.


This monograph has been modified to include the generic and brand name in many instances.

Patient Information

PREVACID
(prev-a-sid)
(lansoprazole) Delayed-Release Capsules and

PREVACID SoluTab
(prev-a-sid sol-u-tab)
(lansoprazole) Delayed-Release Orally Disintegrating Tablets

Read this Medication Guide before you start taking PREVACID and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.

What is the most important information that I should know about PREVACID?

PREVACID may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.

PREVACID can cause serious side effects, including:

  • Diarrhea. PREVACID may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection (Clostridium difficile) in your intestines. Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away.
  • Bone fractures. People who take multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may have an increased risk of fractures of the hip, wrist or spine. You should take PREVACID exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone fracture if you take PREVACID.

PREVACID can have other serious side effects. See “What are the possible side effects of PREVACID?”

What is PREVACID?

PREVACID is a prescription medicine called a proton pump inhibitor (PPI). PREVACID reduces the amount of acid in your stomach.

PREVACID is used in adults:

  • for 4 weeks for the healing and symptom relief of duodenal ulcers. The duodenal area is the area where food passes when it leaves the stomach.
  • with certain antibiotics to treat an infection called H. pylori. Sometimes H. pylori bacteria can cause duodenal ulcers. The infection needs to be treated to prevent ulcers from coming back.
  • for continued healing of duodenal ulcers.
  • for up to 8 weeks to heal stomach ulcers.
  • for up to 8 weeks to heal stomach ulcers in some people taking pain medicines called non-steroidal antiinflammatory drugs (NSAIDs).
  • for reducing the risk of stomach ulcers in some people taking NSAIDs.
  • for up to 8 weeks for the relief of heartburn and other symptoms of gastroesophageal reflux disease (GERD).
    GERD happens when acid in your stomach backs up into the tube (esophagus) that connects your mouth to your stomach. This may cause a burning feeling in your chest or throat, sour taste or burping.
  • for 8 weeks to heal the acid-related damage to the lining of the esophagus (called erosive esophagitis) and to relieve symptoms. If needed, your doctor may prescribe another 8 weeks of PREVACID.
  • for continued healing of erosive esophagitis.
  • for the long-term treatment of conditions where your stomach makes too much acid. This includes a condition called Zollinger-Ellison syndrome.

PREVACID is used in children and adolescents (ages 1 to 17):

  • for up to 12 weeks to treat GERD and erosive esophagitis in children 1 to 11 years old.
  • for up to 8 weeks to treat GERD and erosive esophagitis in adolescents 12 to 17 years old.

PREVACID is not effective for symptoms of GERD in children under the age of 1 year.

Who should not take PREVACID?

  • Do not take PREVACID if you are allergic to lansoprazole or any of the other ingredients in PREVACID. See the end of this Medication Guide for a complete list of ingredients in PREVACID.

What should I tell my doctor before taking PREVACID?

Before you take PREVACID, tell your doctor if you:

  • have been told that you have low magnesium levels in your blood.
  • have liver problems
  • have phenylketonuria. PREVACID SoluTab contains aspartame.
  • have any other medical conditions
  • are pregnant or plan to become pregnant. It is not known if PREVACID will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if PREVACID passes into your breast milk. You and your doctor should decide if you will take PREVACID or breastfeed. You should not do both. Talk to your doctor about the best way to feed your baby if you take PREVACID.

Tell your doctor about all the medicines you take, including prescription and non-prescription drugs, vitamins, and herbal supplements. PREVACID may affect how other medicines work, and other medicines may affect how PREVACID works.

Especially tell your doctor if you take:

  • atazanavir (Reyataz)
  • erlotinib (Tarceva)
  • digoxin (Lanoxin)
  • a product that contains iron
  • ketoconazole (Nizoral)
  • warfarin (Coumadin, Jantoven)
  • tacrolimus (Prograf)
  • theophylline (Theo-24, Elixophyllin, Theochron, Theolair)
  • an antibiotic that contains ampicillin or clarithromycin
  • methotrexate
  • mycophenolate mofetil (Cellcept)

Ask your doctor or pharmacist for a list of these medicines if you are not sure.

Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I take PREVACID?

  • Take PREVACID exactly as prescribed by your doctor.
  • Do not change your dose or stop taking PREVACID without talking to your doctor.
  • You should take PREVACID before eating.
  • PREVACID Delayed-Release Capsules:
    • You should swallow PREVACID Delayed-Release Capsules whole.
    • Do not crush or chew PREVACID Delayed-Release Capsules.
    • If you have trouble swallowing a whole capsule, you can open the capsule and take the contents with certain foods or juices. See the “Instructions for Use” at the end of this Medication Guide for instructions on how to take PREVACID capsules with certain foods and juices.
    • See the “Instructions for Use” at the end of this Medication Guide for instructions on how to mix and give PREVACID capsules through a nasogastric tube.
  • PREVACID SoluTab:
    • is a tablet that melts in your mouth with or without water.
    • Do not break, cut or chew the tablets.
    • See the “Instructions for Use” at the end of this Medication Guide for instructions on how to mix and give PREVACID SoluTab tablets through a syringe and nasogastric tube.
  • If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Just take the next dose at your regular time. Do not take 2 doses at the same time.
  • If you take too much PREVACID, call your doctor right away.

What are the possible side effects of PREVACID?

PREVACID can cause serious side effects, including:

  • See “What is the most important information that I should know about PREVACID?”
  • Vitamin B12 deficiency. PREVACID reduces the amount of acid in your stomach. Stomach acid is needed to absorb vitamin B12 properly. Talk with your doctor about the possibility of vitamin B12 deficiency if you have been on PREVACID for a long time (more than 3 years).
  • Low magnesium levels in your body. This problem can be serious. Low magnesium can happen in some people who take a proton pump inhibitor medicine for at least 3 months. If low magnesium levels happen, it is usually after a year of treatment. You may or may not have symptoms of low magnesium.

Tell your doctor right away if you develop any of these symptoms:

  • seizures
  • dizziness
  • abnormal or fast heartbeat
  • jitteriness
  • jerking movements or shaking (tremors)
  • muscle weakness
  • spasms of the hands and feet
  • cramps or muscle aches
  • spasm of the voice box

Your doctor may check the level of magnesium in your body before you start taking PREVACID, or during treatment; if you will be taking PREVACID for a long period of time.

The most common side effects of PREVACID in adults and children include:

  • diarrhea
  • stomach pain
  • nausea
  • constipation
  • headache

Other side effects:

  • Serious allergic reactions. Tell your doctor if you get any of the following symptoms with PREVACID.
    • rash
    • face swelling
    • throat tightness
    • difficulty breathing

Your doctor may stop PREVACID if these symptoms happen.

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of PREVACID. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store PREVACID?

  • Store PREVACID at room temperature between 68°F to 77°F (20°C to 25°C).

Keep PREVACID and all medicines out of the reach of children.

General information about PREVACID

Medicines are sometimes prescribed for conditions other than those listed in a Medication Guide. Do not use PREVACID for conditions for which it was not prescribed. Do not give PREVACID to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about PREVACID. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about PREVACID that is written for healthcare professionals.

For more information go to www.PREVACID.com or call 1-877-825-3327.

What are the ingredients in PREVACID?

Active ingredient: lansoprazole.

Inactive ingredients in PREVACID Delayed-Release Capsules:

Sugar sphere, sucrose, methacrylic acid copolymer, low substituted hydroxypropyl cellulose, starch, magnesium carbonate, talc, polyethylene glycol, titanium dioxide, polysorbate 80, hydroxypropyl cellulose, colloidal silicon dioxide, D&C Red No. 28, FD&C Blue No. 1, and FD&C Red No. 40.

In addition PREVACID 15 mg Capsule only: FD&C Green No. 3.

Inactive ingredients in PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets:

Mannitol, methacrylic acid, hydroxypropyl cellulose, lactose monohydrate-microcrystalline cellulose sphere, triethyl citrate, crospovidone, polyacrylate, magnesium carbonate, aspartame, glyceryl monostearate, hypromellose, magnesium stearate, citric acid, titanium dioxide, talc, artificial strawberry flavor, polyethylene glycol, polysorbate 80 and ferric oxide.

PREVACID SoluTab contains phenylalanine 2.5 mg per 15 mg Tablet and 5.1 mg per 30 mg Tablet.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Instructions for Use

PREVACID
(prev-a-sid)
(lansoprazole) Delayed-Release Capsules and

PREVACID SoluTab
(prev-a-sid sol-u-tab)
(lansoprazole) Delayed-Release Orally Disintegrating Tablets

PREVACID Delayed-Release Capsules

  • Swallow PREVACID Delayed-Release Capsules whole. Do not crush or chew them.
  • You should take PREVACID before eating.

PREVACID Delayed-Release Capsule with certain food:

You can only use applesauce, ENSURE pudding, cottage cheese, yogurt or strained pears.

  1. Open the capsule.
  2. Sprinkle the granules on 1 tablespoon of either applesauce, ENSURE pudding, cottage cheese, yogurt or strained pears.
  3. Swallow right away.

PREVACID Delayed-Release Capsule with certain juices:

You can only use apple juice, orange juice or tomato juice.

  1. Open the capsule.
  2. Sprinkle the granules into 60 mL (about ¼ cup) of either apple juice, orange juice or tomato juice.
  3. Stir.
  4. Swallow right away.
  5. To make sure that the entire dose is taken, rinse the glass with ½ cup or more of juice to get out any leftover granules. Swallow the juice right away.

PREVACID Delayed-Release Capsules through a nasogastric tube (NG tube) 16 French or larger, as prescribed by your doctor:

You can only use apple juice.

  1. Open the capsule and empty the granules into a syringe.
  2. Do not break or crush the granules.
  3. Mix with 40 mL of apple juice. Do not use other liquids.
  4. Attach the syringe to the NG tube and give the medicine in the syringe through the NG tube into the stomach.
  5. After giving the granules, flush the NG tube with more apple juice to clear the tube.

PREVACID should not be used in foods or liquids not listed above.

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets

  1. Do not chew, crush, cut or break tablets.
  2. Put the tablet on the tongue and let it dissolve, with or without water.
  3. Swallow after the tablet dissolves.
  4. The tablet usually dissolves in less than 1 minute.

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets with an oral syringe:

  1. Put a 15 mg tablet in an oral syringe and add 4 mL of water, or put a 30 mg tablet in an oral syringe and add 10 mL of water.
  2. Shake the syringe gently to dissolve the tablet quickly.
  3. After the tablet has dissolved, give the mixture within 15 minutes.
  4. To make sure that the entire dose is taken, refill the syringe with about 2 mL (5 mL for the 30 mg tablet) of water, shake gently, and give the water in the syringe.

PREVACID SoluTab Delayed-Release Orally Disintegrating Tablets through a nasogastric tube (NG tube) 8 French or larger, as prescribed by your doctor:

  1. Put a 15 mg tablet in a syringe and add 4 mL of water, or put a 30 mg tablet in a syringe and add 10 mL of water.
  2. Shake the syringe gently to dissolve the tablet quickly.
  3. After the tablet has dissolved, give the mixture in the syringe through the NG tube into the stomach within 15 minutes.
  4. Refill the syringe with about 5 mL of water, shake gently, and flush the NG tube.

How should I store PREVACID?

  • Store PREVACID at room temperature between 68°F to 77°F (20°C to 25°C).

Keep PREVACID and all medicines out of the reach of children.

This Instruction for Use has been approved by the U.S. Food and Drug Administration.


This monograph has been modified to include the generic and brand name in many instances.

Consumer Overview Uses

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

 

LANSOPRAZOLE DELAYED-RELEASE CAPSULE - ORAL

 

(lan-SO-pruh-zole)

 

COMMON BRAND NAME(S): Prevacid

 

USES: Lansoprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and persistent cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Lansoprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

If you are self-treating with this medication, over-the-counter lansoprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away.

For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

 

HOW TO USE: Read the Medication Guide and the Patient Information Leaflet if available from your pharmacist before you start taking lansoprazole and each time you get a refill.

Take this medication by mouth as directed by your doctor, usually once daily, before a meal. If you are self-treating, follow all directions on the product package. Dosage and length of treatment are based on your medical condition and response to treatment. Do not increase your dose or take this drug more often than directed. If you have any questions, ask your doctor or pharmacist.

Do not crush or chew the capsules. Swallow the medication whole. If you have trouble swallowing the capsule, you may open the capsule and sprinkle its contents on a spoonful of soft food (such as applesauce, cottage cheese, yogurt) and swallow the mixture right away without chewing it. Or you may empty the capsule's contents into a small amount (2 ounces or 60 milliliters) of juice, stir, and drink the mixture right away without chewing it. Then rinse the glass with more juice and drink to make sure you have taken the entire dose. Do not prepare the mixture ahead of time for later use. Doing so may destroy the drug.

If you are giving this medication through a tube into the stomach (nasogastric tube), ask your health care professional for detailed instructions on how to properly mix and give it.

If needed, antacids may be taken along with this medication. If you are also taking sucralfate, take lansoprazole at least 30 minutes before sucralfate.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. Continue to take this medication for the prescribed length of treatment even if you are feeling better. If you are self-treating with the over-the-counter product, do not take it for more than 14 days unless directed by your doctor.

Tell your doctor if your condition persists or worsens. If you are self-treating, tell your doctor if your heartburn persists after 14 days or if you need to use this medication more than once every 4 months. If you think you may have a serious medical problem, get medical help right away.

 

 

Consumer Overview Side Effect

SIDE EFFECTS: Diarrhea, abdominal pain, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

If your doctor has directed you to use this product, remember that he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: symptoms of a low magnesium blood level (such as unusually fast/slow/irregular heartbeat, persistent muscle spasms, seizures).

This medication may rarely cause a severe intestinal condition (Clostridium difficile-associated diarrhea) due to a type of bacteria. Do not use anti-diarrhea products or narcotic pain medications if you have any of the following symptoms because these products may make them worse. Tell your doctor right away if you develop: persistent diarrhea, abdominal or stomach pain/cramping, fever, blood/mucus in your stool.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

 

Read the Prevacid (lansoprazole) Side Effects Center for a complete guide to possible side effects

Learn More »

PRECAUTIONS: Before taking lansoprazole, tell your doctor or pharmacist if you are allergic to it; or to similar drugs (such as dexlansoprazole, omeprazole, pantoprazole); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease.

Some symptoms may actually be signs of a more serious condition. Get medical help right away if you have: heartburn with lightheadedness/sweating/dizziness, chest/jaw/arm/shoulder pain (especially with shortness of breath, unusual sweating), unexplained weight loss.

In addition, before you self-treat with this medication, get medical help right away if you have any of these signs of a serious condition: trouble/pain swallowing food, bloody vomit, vomit that looks like coffee grounds, bloody/black stools, heartburn for over 3 months, frequent chest pain, frequent wheezing (especially with heartburn), nausea/vomiting, stomach pain.

Proton pump inhibitors (such as lansoprazole) may increase your risk for bone fractures, especially with longer use, higher doses, and in older adults. Talk with your doctor or pharmacist about ways to prevent bone loss/fracture, such as by taking calcium (such as calcium citrate) and vitamin D supplements.

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this medication passes into breast milk. However, similar drugs pass into breast milk. The effects on a nursing infant are unknown. Consult your doctor before breast-feeding.

Consumer Overview Missed Dose

DRUG INTERACTIONS: See also How to Use section.

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Some products that may interact with this drug include: methotrexate (especially high-dose treatment).

Some products need stomach acid so that the body can absorb them properly. Lansoprazole decreases stomach acid, so it may change how well these products work. Some affected products include ampicillin, atazanavir, erlotinib, nelfinavir, rilpivirine, certain azole antifungals (itraconazole, ketoconazole, posaconazole), among others.

Lansoprazole is very similar to dexlansoprazole. Do not use medications containing dexlansoprazole while using lansoprazole.

 

OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

 

NOTES: If your doctor has prescribed this medication for you, do not share it with others.

If your doctor instructs you to use this medication regularly for a long time, laboratory and medical tests (such as a magnesium blood test) may be performed periodically to monitor your progress or check for side effects. Keep all regular medical and laboratory appointments.

 

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

 

STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

 

Information last revised March 2014. Copyright(c) 2014 First Databank, Inc.

Patient Detailed Side Effect

Brand Names: First Lansoprazole, Prevacid, Prevacid OTC, Prevacid SoluTab

Generic Name: lansoprazole (Pronunciation: lan SOE pra zol)

  • What is lansoprazole (Prevacid)?
  • What are the possible side effects of lansoprazole (Prevacid)?
  • What is the most important information I should know about lansoprazole (Prevacid)?
  • What should I discuss with my healthcare provider before taking lansoprazole (Prevacid)?
  • How should I take lansoprazole (Prevacid)?
  • What happens if I miss a dose (Prevacid)?
  • What happens if I overdose (Prevacid)?
  • What should I avoid while taking lansoprazole (Prevacid)?
  • What other drugs will affect lansoprazole (Prevacid)?
  • Where can I get more information?

What is lansoprazole (Prevacid)?

Lansoprazole is a proton pump inhibitors. Lansoprazole decreases the amount of acid produced in the stomach.

Lansoprazole is used to treat and prevent stomach and intestinal ulcers, erosive esophagitis (damage to the esophagus from stomach acid), and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome.

Lansoprazole is not for immediate relief of heartburn symptoms.

Lansoprazole may also be used for purposes not listed in this medication guide.

Lansoprazole 15 mg ODT-TEV

round, white, imprinted with 15

What are the possible side effects of lansoprazole (Prevacid)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using lansoprazole and call your doctor at once if you have symptoms of low magnesium:

  • dizziness, confusion;
  • fast or uneven heart rate;
  • jerky muscle movements;
  • feeling jittery;
  • diarrhea that is watery or bloody;
  • muscle cramps, muscle weakness or limp feeling;
  • cough or choking feeling; or
  • seizure.

Less serious side effects may include:

  • headache;
  • nausea, stomach pain;
  • mild diarrhea; or
  • constipation.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Prevacid (lansoprazole) Side Effects Center for a complete guide to possible side effects

Learn More »

What is the most important information I should know about lansoprazole (Prevacid)?

Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.

Ask a doctor or pharmacist if it is safe for you to take lansoprazole if you have liver disease, or low levels of magnesium in your blood.

Lansoprazole is not for immediate relief of heartburn symptoms.

Some conditions are treated with a combination of lansoprazole and antibiotics. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.

If you also take sucralfate (Carafate), avoid taking it at the same time you take lansoprazole. Sucralfate can make it harder for your body to absorb lansoprazole. Wait at least 30 minutes after taking lansoprazole before you take sucralfate.

Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.

Prevacid 24HR should be taken only once every 24 hours for 14 days. It may take up to 4 days for full effect. Do not take more than one tablet every 24 hours.

Allow at least 4 months to pass before you start another 14-day treatment with Prevacid 24HR. Call your doctor if you have additional symptoms and need treatment before the 4 months has passed.

Side Effects Centers
  • Prevacid

Patient Detailed How Take

What should I discuss with my healthcare provider before taking lansoprazole (Prevacid)?

Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.

You should not use this medication if you are allergic to lansoprazole.

Ask a doctor or pharmacist if it is safe for you to take lansoprazole if you have liver disease, or low levels of magnesium in your blood.

Do not use over-the-counter lansoprazole (Prevacid 24HR) without the advice of a doctor if you have:

  • trouble or pain with swallowing;
  • bloody or black stools;
  • vomit that looks like blood or coffee grounds;
  • heartburn that has lasted for over 3 months;
  • frequent chest pain;
  • heartburn with wheezing;
  • unexplained weight loss;
  • nausea or vomiting;
  • stomach pain; or
  • an electrolyte imbalance or metabolic disorder.

Some conditions are treated with a combination of lansoprazole and antibiotics. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.

Taking a proton pump inhibitor such as lansoprazole may increase your risk of bone fracture in the hip, wrist, or spine. This effect has occurred mostly in people who have taken the medication long term or at high doses, and in those who are age 50 and older. It is not clear whether lansoprazole is the actual cause of an increased risk of fracture. Before you take this medication, tell your doctor if you have osteoporosis or osteopenia (low bone mineral density).

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether lansoprazole passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Some forms of lansoprazole may contain phenylalanine. Tell your doctor if you have phenylketonuria.

Do not give this medication to a child younger than 1 year old.

How should I take lansoprazole (Prevacid)?

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Lansoprazole is usually taken before eating. Follow your doctor's instructions.

Do not crush or break a delayed-release capsule. Swallow it whole. Breaking the pill may cause too much of the drug to be released at one time.

If you are unable to swallow a delayed-release capsule whole: Open the capsule and sprinkle the medicine into a spoonful of pudding, applesauce, yogurt, cottage cheese, strained pears, or a nutritional drink such as Ensure. Swallow this mixture right away without chewing. Do not save the mixture for later use. Discard the empty capsule.

You may also dissolve the medicine from a lansoprazole capsule in 2 ounces (1/4 cup) of apple juice, orange juice, or tomato juice. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more juice to the same glass, swirl gently and drink right away.

Dissolve the oral granules in 2 tablespoons of water. Use only water when mixing lansoprazole oral granules. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.

Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

To take lansoprazole orally disintegrating tablet: Use dry hands to remove the tablet and place it in your mouth. It will begin to dissolve right away. Allow the tablet to dissolve in your mouth without chewing, swallowing several times as it dissolves.

The orally disintegrating tablet should not be given with an oral syringe or given through a nasogastric (NG) feeding tube. The tablet may not dissolve completely and could clog the syringe or tube.

Prevacid 24HR should be taken only once every 24 hours for 14 days. Take the medicine in the morning before you eat breakfast. It may take up to 4 days for full effect. Do not take more than one tablet every 24 hours.

Allow at least 4 months to pass before you start another 14-day treatment with Prevacid 24HR. Call your doctor if you have additional symptoms and need treatment before the 4 months has passed.

Do not crush, chew, or break a Prevacid 24HR capsule. Swallow the pill whole.

Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.

Call your doctor if your symptoms do not improve or if they get worse while you are taking this medicine.

Store at room temperature away from moisture and heat. Do not freeze the liquid medicine and protect it from light.

Side Effects Centers
  • Prevacid

Patient Detailed Avoid Taking

What happens if I miss a dose (Prevacid)?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Prevacid)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking lansoprazole (Prevacid)?

This medication can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking lansoprazole and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

If you also take sucralfate (Carafate), avoid taking it at the same time you take lansoprazole. Sucralfate can make it harder for your body to absorb lansoprazole. Wait at least 30 minutes after taking lansoprazole before you take sucralfate.

What other drugs will affect lansoprazole (Prevacid)?

Tell your doctor about all other medicines you use, especially:

  • ampicillin (Principen, Unasyn);
  • atazanavir (Reyataz);
  • digoxin (Lanoxin, Lanoxicaps);
  • iron (Feosol, Mol-Iron, Fergon, Femiron, others);
  • ketoconazole (Nizoral);
  • methotrexate (Rheumatrex, Trexall);
  • theophylline (such as Elixophyllin, Respbid, Slo-Bid, Theobid, Theoclear, Theo-Dur, Uniphyl);
  • a blood thinner such as warfarin (Coumadin, Jantoven); or
  • a diuretic (water pill).

This list is not complete and other drugs may interact with lansoprazole. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about lansoprazole.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 11.01. Revision date: 7/6/2012.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers
  • Prevacid

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI